(R) -Bemcentinib

(R) -Bemcentinib ((R) -R428) is the R-isomer of Bemcentinib (HY-15150) . Bemcentinib (R428) is a selective, orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib blocks tumor metastasis and prolongs survival in metastatic breast cancer models[1][2][3].

Product Specifications

CAS Number

[1037624-76-2]

Product Name Alternative

(R) -R428; (R) -BGB324

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Drug Isomer

Related Pathways

Others

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

NC=1N(C=2C=C3C(C=4C(CCC3)=CC=CC4)=NN2)N=C(NC=5C=C6C(=CC5)CC[C@H](CC6)N7CCCC7)N1

Molecular Formula

C30H34N8

Molecular Weight

506.66

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011 Dec;131 (12) :2448-57. |[2]Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010 Feb 15;70 (4) :1544-54.|[3]Lijnen HR, et al. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011 May;337 (2) :457-64.